---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124067"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:46:54.462745+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Karyopharm reduces office space by 46,278 sq ft, extends lease for remaining space through 2030

## Summary
- Reduces leased premises by 46,278 rentable square feet (from 98,502 to 52,224) effective Sept 30, 2025.
- Term for remaining 52,224 sq ft extended five years through Sept 30, 2030, with annual rent escalation.
- Annual base rent for remaining space starts at $35.75/sq ft ($1.87M) and rises to $39.75/sq ft ($2.08M) by year 5.
- Landlord provides $2,219,520 tenant improvement allowance ($42.50/sq ft) for work in the retained premises.
- Tenant surrenders vacated portion on Sept 30, 2025, without required removal of certain initial alterations.

## SEC filing metadata
- accession: 0000950170-24-124067
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017024124067/0000950170-24-124067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017024124067/kpti-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124067
- JSON: https://secwatch.observer/filing/0000950170-24-124067.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.